Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists

This publication has 54 references indexed in Scilit:

• Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors
  JNCI Journal of the National Cancer Institute, 1996
• Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer
  British Journal of Cancer, 1996
• Antiestrogens: Mechanisms and actions in target cells
  The Journal of Steroid Biochemistry and Molecular Biology, 1995
• A current view of tamoxifen for the treatment and prevention of breast cancer
  British Journal of Pharmacology, 1993
• Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.
  Proceedings of the National Academy of Sciences, 1992
• Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
  New England Journal of Medicine, 1992
• Endocrine therapy for advanced breast cancer: A review
  Breast Cancer Research and Treatment, 1992
• Endocrine Pharmacology of Antiestrogens as Antitumor Agents*
  Endocrine Reviews, 1990
• Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.
  Proceedings of the National Academy of Sciences, 1990
• Endocrine Treatment of Breast Cancer in Women
  Endocrine Reviews, 1990